Sarepta Therapeutics (SRPT) Shares Resume Trading; Now Up 82% on FDA Eteplirsen Approval

September 19, 2016 9:59 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Sarepta Therapeutics (NASDAQ: SRPT) is up 82% after re-opening on accelerated approval for eteplirsen

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk, Trading Halts

Add Your Comment